OMRON Healthcare Surpasses 50 Million Nebulizers Sold

  • 등록 2025.11.28 16:00:00
크게보기

[ 메디채널 김갑성 기자 ] - Easing Burden of Respiratory Diseases Worldwide since 1978 -

 

KYOTO, Japan, Nov. 28, 2025 -- OMRON HEALTHCARE Co., Ltd., a global leader in the field of clinically proven, innovative medical equipment for home health monitoring and treatment, announced that cumulative sales of its nebulizers have surpassed 50 million units. This proud milestone underscores the company's long-standing commitment to helping people around the world to live healthier lives through management of respiratory conditions.

 

Image1:
https://cdn.kyodonewsprwire.jp/prwfile/release/M000242/202510308084/_prw_PI1fl_gvhJ3KRi.png

 

Internationally, respiratory diseases are a growing issue, particularly in emerging economies. According to the World Health Organization, some 339 million people suffer from asthma worldwide, with an estimated 3.5 million deaths each year due to Chronic Obstructive Pulmonary Disorder (COPD). Nebulizers, which convert liquid medications into a fine mist that can be inhaled directly into the lungs, are a key tool for easing the burden of respiratory diseases in children and adults alike.

 

Almost five decades as a trusted partner in respiratory therapy

 

Since the launch of its first nebulizer in 1978, OMRON Healthcare has pioneered the development of compact home-use devices that deliver medical-grade respiratory treatment outside of clinical settings, prioritizing ease of use for families and patients of all ages, from young children to older adults.

 

Image2:
https://cdn.kyodonewsprwire.jp/prwfile/release/M000242/202510308084/_prw_PI2fl_5D7pQUoU.png

 

Design landmarks ranging from the first ultrasonic models to portable mesh-type and low-noise compressor technologies have made medication delivery more consistent and convenient for millions of users worldwide, including those living with chronic and acute respiratory ailments such as asthma, COPD, RSV bronchitis, cystic fibrosis, and a range of physical disabilities.

 

Image3:
https://cdn.kyodonewsprwire.jp/prwfile/release/M000242/202510308084/_prw_PI3fl_C3N67qeX.png

 

Comment from Tomohiro Kukita, Senior Manager, Product Planning Strategy HQ of OMRON HEALTHCARE Co., Ltd.: https://kyodonewsprwire.jp/attach/202510308084-O1-S6J3q6El.pdf

 

About OMRON Healthcare: https://kyodonewsprwire.jp/attach/202510308084-O2-W1MisE02.pdf

 

For more information, please visit:
Website: https://healthcare.omron.com/
LinkedIn: https://www.linkedin.com/company/omron-healthcare-co-ltd-/

 

김갑성 기자 mdkks1004@naver.com
Copyright @메디채널 Corp. All rights reserved.

발행인 : 최희정 | 편집인 : 김갑성 | 등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 | 주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동) Copyright @메디채널 Corp. All rights reserved.